Jonathan Rainer, MD
Physical Medicine & Rehabilitation · Daphne, ALNPI 1336274810
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 39.8% of the total. Reporting peaked in 2019 at $1,398 and has fallen 63.9% since, to $505 in 2025. Among physical medicine & rehabilitation clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Arbor Pharmaceuticals, Inc.$364
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$219
- Teva Pharmaceuticals USA, Inc.$198
- Adamas Pharmaceuticals, Inc.$188
- Pacira Therapeutics, Inc.$173
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,451100%
- Education$80%
- Entertainment$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $1,780 |
| Arbor Pharmaceuticals, Inc. | 29 | $364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $219 |
| Teva Pharmaceuticals USA, Inc. | 11 | $198 |
| Adamas Pharmaceuticals, Inc. | 8 | $188 |
| Pacira Therapeutics, Inc. | 9 | $173 |
| UCB, Inc. | 7 | $129 |
| SK Life Science, Inc. | 6 | $129 |
| Lilly USA, LLC | 9 | $125 |
| Zyla Life Sciences, Inc. | 7 | $114 |
| Tanabe Pharma America, Inc. | 7 | $105 |
| Lundbeck LLC | 5 | $97 |
| Scilex Pharmaceuticals Inc. | 6 | $89 |
| Nevro Corp. | 3 | $86 |
| Novartis | 4 | $74 |
| Amgen | 4 | $70 |
| Collegium Pharmaceutical, Inc. | 4 | $62 |
| Globus Medical | 2 | $44 |
| Medtronic | 3 | $42 |
| Biogen | 3 | $41 |
| Avanos Medical | 1 | $39 |
| Tersera Therapeutics LLC | 2 | $37 |
| Vertical Pharmaceuticals, LLC | 2 | $27 |
| Biodelivery Sciences International, Inc. | 2 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Abbott | 1 | $22 |
| Stryker | 1 | $20 |
| Vertex | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Flowonix Medical Incorporated | 1 | $11 |
| Bioventus LLC | 1 | $11 |
| Pfizer | 1 | $11 |
| GRT US Holding, Inc. | 1 | $11 |
How this compares
$4,470 in reported general payments places this provider in the 90th percentile of 104 physical medicine & rehabilitation providers in Alabama.
See all physical medicine & rehabilitation providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 20 | $76,317 |
| NucyntaTapentadol Hcl | 54 | $47,116 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,880 | $44,022 |
| OxycontinOxycodone Hcl | 59 | $32,075 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,020 | $26,972 |
| MovantikNaloxegol Oxalate | 66 | $26,682 |
| BelbucaBuprenorphine Hcl | 52 | $24,883 |
| Buprenorphine | 79 | $20,928 |
| Lidocaine | 173 | $16,609 |
| Pregabalin | 625 | $15,399 |
| Gabapentin | 1,219 | $13,764 |
| Xtampza ErOxycodone Myristate | 21 | $12,400 |
| Tizanidine Hcl | 1,241 | $11,652 |
| ZtlidoLidocaine | 24 | $8,412 |
| Diclofenac Sodium | 366 | $7,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er | $62 | $84,399127 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $219 | $76,31720 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $89 | $8,41224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 physical medicine & rehabilitation providers in Alabama.
Other physical medicine & rehabilitation in Daphne
- David ThomasonDaphne$7K
- Fairen Walker-MccarterDaphne$980
- Don McCormickBirmingham$22K
- Bradly GoodmanBirmingham$15K
- Nelson Santos AgostoBirmingham$14K
- John PantuoscoBirmingham$12K
- Ross LumsdenBirmingham$11K
- Michael RosemoreBessemer$10K
- Stevon BoyettAthens$8K
- Matthew BerkeBirmingham$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.